Our newsletter, the Astria Connection: HAE, is for those impacted by HAE. View our most recent newsletters here to learn more about navenibart (STAR-0215) in clinical development for HAE, our goals, and Astria’s commitment to HAE.
I want to receive electronic communications from Astria Therapeutics (“Astria” or “we”) and I consent to the processing of the personal data I have provided for this purpose (which consent complies with applicable regulations, including Article 6(1)(a) of the EU General Data Protection Regulation).
To receive electronic communications from Astria, Astria uses the so-called double opt-in procedure. After you have consented to receive electronic communications from us on our Website, we will send you a message to the indicated email address asking for your confirmation. If you do not confirm that you would like to receive email communications, your request will automatically be deleted. You may at any time withdraw your consent to receive our electronic communications, in which case we will also delete your personal data connected to receiving our electronic communications. To declare that you wish to unsubscribe, you may use the respective link included in our communications or contact us at privacy@astriatx.com. Further details about our practices are available in our Website Privacy Notice.